EU to provide incentives for “orphan” drugsBMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7245.1294 (Published 13 May 2000) Cite this as: BMJ 2000;320:1294
- Rory Watson
The European Union has introduced new legislation designed to encourage pharmaceutical companies to develop treatments for “orphan” (rare)diseases that affect fewer than five people in every 10000 within the 15 member bloc.
Since the beginning of this month companies have been able to apply to the London based European Agency for the Evaluation of Medicinal Products …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial